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Change in therapy was deﬁned as having a recorded prescription
for an insomnia treatment other than the index study medica-
tion (estazolam, ﬂurazepam, quazepam, temazepam, triazolam,
low-dose trazodone, zolpidem tartrate or zaleplon) during the
post-index period, which included overlapping augmentation or
complete therapy switch. Economic costs included direct medical
and pharmacy expenditures. One-year follow-up costs were
compared using Wilcoxon tests for bivariate analyses and gen-
eralized linear models with gamma functions for multivariate
comparisons. RESULTS: Approximately 88% of the sample did
not have a change in insomnia treatment. Patients on monother-
apy (n = 24,540) differed from patients altering therapy (n =
3267) with respect to age, gender and baseline Deyo-Charlson
score. Patients altering therapy had a higher frequency of insom-
nia diagnoses (22.4% vs. 11.4%, p < 0.001) and other comor-
bidities than maintainers. Unadjusted and adjusted direct
medical costs for patients with changes in insomnia therapy 
were approximately 66% and 67% greater than patients who
remained on their index therapy ($16,053 vs. $9798, p < 0.001;
and $16,580 vs. $9942, p < 0.001), respectively. Similar results
were also observed among patients with available productivity
data. CONCLUSION: Results point to a signiﬁcant relationship
between changes in therapy and economic burden. Further
research would be warranted to ﬁnd the reasons for therapy
change and the potential economic beneﬁt of newer therapies.
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OBJECTIVES: Generic substitution may result in lower cost
savings than expected, particularly for narrow therapeutic index
products such as antiepileptic drugs (AEDs). Possible lower efﬁ-
cacy and adverse effects from generic substitution of AEDs may
increase overall pharmacy utilization, thus counterbalancing per-
pill savings. The objective of this study was to analyze the eco-
nomic impact of government-mandated switching from branded
to generic lamotrigine. METHODS: In a Canadian public payer
pharmacy claims database, patients using branded lamotrigine
in 2002 and converted to generic lamotrigine in 2003 were
observed 1/2003–3/2006. For the generic period, the observed
per-patient monthly drug costs were calculated as the sum of
costs for lamotrigine, other AEDs and non-AEDs. Expected per-
patient drug costs were estimated as the costs attributed to no
change in lamotrigine dose, nor in other pharmacy utilization.
Differences between observed and expected costs were com-
pared. RESULTS: Among 1142 branded lamotrigine users,
overall average monthly drug costs were expected to decrease by
16.4 percent due to lower pill costs. Instead, these costs fell by
only 6.4 percent, from $186.46 during the brand period to
$174.48 during the generic period. Because of dosage changes,
lamotrigine costs decreased by 28.2%, instead of the anticipated
31.9% (p < 0.001). Other AED costs increased by 18.5% rather
than 1.1% (p < 0.001), while non-AED drug cost increased by
25.1 percent rather than 6.4% (p < 0.001), due to increased
pharmacy utilization. CONCLUSION: These signiﬁcantly lower
than expected drug cost reductions suggest that generic lamot-
rigine may be less effective than its branded counterpart and
hence increases needs for other treatments. Payers should weigh
the smaller than expected cost reduction against possible
decrease in treatment effectiveness to determine the desirability
of mandatory switching to generic lamotrigine.
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OBJECTIVES: To assess association between long-term (>12
months) versus short-term (<12 months) use of migraine pre-
vention medication and resource utilization/lost productivity.
METHODS: A validated self-administered headache question-
naire was mailed to 24,000 severe headache sufferers (age > 18
years) selected as a random sub-sample from a prior survey of
120,000 households representative of the US population.
Respondents completed a survey on headache features, fre-
quency, impairment, resource use, and productivity. Migraine
cases were identiﬁed using the International Classiﬁcation of
Headache Disorders, 2nd Edition (ICHD-2) and were included
in this analysis if they reported current use of a preventive med-
ication for migraine (i.e., topiramate, divalproex, beta blockers
or tricyclic antidepressants). Long-term (LT) users of preventive
medication were compared with short-term (ST) users.
RESULTS: A total of 16,577 surveys were returned (69%
response rate) and 11,388 cases met the ICHD-2 deﬁnition for
migraine. 325 migraine cases (220 LT users and 105 ST users)
reported currently taking migraine preventive medication. LT
users reported signiﬁcantly fewer primary care visits than ST
users (140 vs. 330 per 100 patients per year; p < 0.01), fewer
ER visits (46 vs. 79 per 100 patients per year; p = 0.01), fewer
pain clinic visits (12 vs. 60 per 100 patients per year; p < 0.01),
fewer nights in hospital (19 vs. 67 per 100 patients per year; p
< 0.01), fewer days missed at work or school in previous three
months (79 vs. 260 per 100 patients; p < 0.01), and fewer days
where work or school productivity was reduced by >50% in pre-
vious three months because of headaches (337 vs. 476 per 100
patients; p < 0.01). There were no differences between two
groups in neurologist visits. CONCLUSION: Use of long-term
migraine preventive medication can be associated with reduced
headache-related health care resource use and productivity loss.
These ﬁndings are consistent with a positive economic impact of
long-term migraine preventive medication use.
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OBJECTIVES: Assess prevalence of medication non-adherence
to Parkinson’s disease (PD) medications and its association with
symptom progression. METHODS: This retrospective, longitu-
dinal cohort study included older adults enrolled continuously
